Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The company received seven observations in the Form-483
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The company received one observation in the Form-483
Subscribe To Our Newsletter & Stay Updated